Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, OptimizeRx Corp reported revenue of $109M, up 18.8% year over year. Operating margin was 10.7% and net margin 4.7%, on a free-cash-flow margin of 17.0% with capital expenditure at 0.1% of revenue. Every figure is computed directly from OPRX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $109M | 10.7% | 4.7% |
| FY2024 | $92M | -14.9% | -21.8% |
| FY2023 | $72M | -36.9% | -24.6% |
| FY2022 | $62M | -19.7% | -18.3% |
| FY2021 | $61M | 0.6% | 0.6% |
How does OPRX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: ABM · ACIW · ACN · ACVA · ADBE · ADMQ
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.